Funding And Financial PerformanceRegenXBio anticipates that the combined payments from Nippon Shinyaku and ABBV, along with proceeds from potential future sales, could fund cash runway into 2027, supporting further development of its late-stage programs.
Product Development And ApprovalRGX-121 could become the first gene therapy for MPS II with potential FDA approval, marking it as RegenXBio Inc.'s first potential commercial-stage product.
Strategic PartnershipsRegenXBio Inc. has entered a strategic partnership with Nippon Shinyaku for the commercialization of RGX-121 and RGX-111 in the US and Asia, potentially bringing up to $810 million in milestones and royalties.